August 4, 2022
A combination therapy pairing Eisai’s oral tyrosine kinase inhibitor Lenvima (lenvatinib) and US Merck’s anti-PD-1 antibody Keytruda (pembrolizumab) failed to hit its primary goals in a PIII study for the first-line treatment of unresectable hepatocellular carcinoma (HCC), the two companies...read more